[A14-06] Addendum to Commission A13-33 (enzalutamide)



Commission: Commission awarded on 2014-01-23 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Addendum to Commission A13-33 (enzalutamide)  [PDF, 310 kB]Further documents

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Contact address:to the contact form
Linked projects: [A18-80] Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A13-33] Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)
Status: Commission completed

Report documents

Report documents

2014-02-20 Addendum to Commission A13-33 (enzalutamide) 310 kBPDFdownload file

At a glance

Accompanying information

Federal Joint Committee (G-BA)

2014-02-20 A G-BA decision was published.

G-BA documents on this decision

Press releases

2014-02-20 Enzalutamide: IQWiG assessed data subsequently submitted by the manufacturer

Save result list

To save your search result, please copy the link below and paste it into a new tab/window.